“C” Trouble: Class IC Anti-arrhythmic Toxicity
Article Sidebar
Main Article Content
Downloads
Article Details
Copyright (c) 2017 Eng M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82: 2N-9N. Link: https://goo.gl/NjAg38
Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, et al. (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363-1373. Link: https://goo.gl/wfYp5F
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, et al. (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825-1833. Link: https://goo.gl/6X2BD1
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:2071-2104. Link: https://goo.gl/oGiMg6
Piccini JP, Mi X, DeWald TA, Go AS, Hernandez AF, et al. (2012) Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm 9:1403-1408. Link: https://goo.gl/De41A1
Crijns HJ (2005) Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs 65:1651-1667. Link: https://goo.gl/7EHnPa
Reimold SC, Maisel WH, Antman EM (1998) Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol 82: 66N-71N. Link: https://goo.gl/3AZ3Q4
Falk RH, Fogel RI (1994) Flecainide. J Cardiovasc Electrophysiol 5: 964-981. Link:
Cobbe SM, Rae AP, Poloniecki JD, Chong E, Balnave K, et al. (1995) A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation UK Propafenone PSVT Study Group. Circulation 92: 2550-2557. Link: https://goo.gl/MqsaRF
Andrikopoulos GK, Pastromas S, Tzeis S (2015) Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol 7: 76-85. Link: https://goo.gl/gbVUTg
Josephson MA, Ikeda N, Singh BN. (1984) Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol 53: 95B-100B. Link: https://goo.gl/aioVn4
Hellestrand KJ, Nathan AW, Bexton RS, Camm AJ (1984) Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds. Am J Cardiol 53: 30B-38B. Link: https://goo.gl/6U5n38
Morganroth J, Horowitz LN (1984) Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53: 89B-94B. Link: https://goo.gl/ZyEdjd
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-354. Link: https://goo.gl/DMfx3c
Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, et al. (1997) Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 126: 621-625. Link: https://goo.gl/7pkaaN
Alboni P, Botto GL, Baldi N, Luzi M, Russo V, et al. (2004) Outpatient treatment of recentonset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351: 2384-2391. Link: https://goo.gl/L2yAac
Miller JM, Zipes, DP (2012) Therapy for Cardiac Arrhythmias. In Braunwald's heart disease: a textbook of cardiovascular medicine, 9th edition. Edited by R Bonow D. Mann D. Zipes, & P. Libby, Saunders, Philadelphia USA 710-744. Link:
Grant AO (1996) Propafenone: an effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol 7: 353-364. Link: https://goo.gl/dfs5DH
Yeung A, Shanks D, Parwana H, Gin K (2010) Acute propafenone toxicity after two exposures at standard dosing. Can J Cardiol 26: 209-210. Link: https://goo.gl/1xS1Wi
Köppel C, Oberdisse U, Heinemeyer G (1990) Clinical course and outcome in class IC antiarrhythmic overdose. J Toxicol Clin Toxicol 28: 433-444. Link: https://goo.gl/Mg2S1b
Greig J, Groden BM (1995) Persistent electrocardiographic changes after flecainide overdose. Br J Clin Pract 49: 218-219. Link: https://goo.gl/QMfK3n
Brubacher J (2004) Bicarbonate therapy for unstable propafenone-induced wide complex tachycardia. CJEM 6: 349-356. Link: https://goo.gl/YHtJ38
Dirks E, Gieshoff B, Stahlmann R, Wehr M, Hager W (1990) Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?. Z Kardiol 79: 54-59. Link: https://goo.gl/XYmsiu
Borgeat A, Biollaz J, Freymond B, Bayer-Berger M, Chiolero R (1988) Hemofiltration clearance of flecainide in a patient with acute renal failure. Intensive Care Med 14: 236-237. Link: https://goo.gl/rm5TvH
Burgess ED, Duff HJ (1989) Hemodialysis removal of propafenone. Pharmacotherapy 9: 331-333. Link: https://goo.gl/6XKSzM
Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR (2013) A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol 36: e87-89. Link: https://goo.gl/GjL3KG
Moussot PE, Marhar F, Minville V, Vallé B, Dehours E, et al. (2011) Use of intravenous lipid 20% emulsion for the treatment of a voluntary intoxication of flecainide with refractory shock. Clin Toxicol (Phila) 49: 514. Link: https://goo.gl/rguk58
ten Tusscher BL, Beishuizen A, Girbes AR, Swart EL, van Leeuwen RW (2011) Intravenous fat emulsion therapy for intentional propafenone intoxication. Clin Toxicol (Phila) 49: 701. Link: https://goo.gl/xsUaz7
Jacob J, Heard K (2011) Second case of the use of intravenous fat emulsion therapy for propafenone toxicity. Clin Toxicol (Phila) 49: 946-947. Link: https://goo.gl/Tcd9S9
American College of Medical Toxicology (2011) ACMT position statement: interim guidance for the use of lipid resuscitation therapy. J Med Toxicol 7: 81-82. Link: https://goo.gl/PpXxFo
Vivien B, Deye N, Mégarbane B, Marx JS, Leprince P, et al. (2010) Extracorporeal life support in a case of fatal flecainide and betaxolol poisoning allowing successful cardiac allograft. Ann Emerg Med 56: 409-412. Link: https://goo.gl/xXJQ4q
Auzinger GM, Scheinkestel CD (2001) Successful extracorporeal life support in a case of severe flecainide intoxication. Crit Care Med 29: 887-890. Link: https://goo.gl/rJ4nga